Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.       Anmelden     oder      Jetzt abonnieren!

Archiv: Alle Kategorien

ASMALLWORLD AG (SWX: ASWN): Hansainvest erhöht Anteil an der ASMALLWORLD AG auf über 10% » Report
Matthias Huenerwadel wird CEO der Zehnder Group » Report
Significant shareholders - Significant shareholdings in companies whose equity securities are listed on SIX Swiss Exchange. » SIX
Bedeutende Aktionäre - Bedeutende Beteiligungen an Gesellschaften, deren Beteiligungspapiere an SIX Swiss Exchange kotiert sind. » SIX
Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid » Report
HBM Healthcare Investments: Erfolgreicher Börsengang von Y-mAbs Therapeutics erhöht Inneren Wert je HBM-Aktie um CHF 4.82 (+2.7%) » Report
SGS Implements Renovo™ Program in Ghana » Report
BIS Quarterly Review: Divergences widen in markets » Report
BIS Quarterly Review: Regulating cryptocurrencies: assessing market reactions » B.I.S.
Swiss Re: Agostino Galvagni has decided to step down, Andreas Berger will succeed him as CEO Corporate Solutions and member of the Group Executive Committee » Report
Aus dem Zentrum Malley wird die Vaudoise Aréna » Report
Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness » Report
New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD » Report
STOXX Changes Composition Of Blue-Chip Indices » Report
STOXX Changes Composition Of Benchmark Indices » Report
ein schönes Wochenende, have a great weekend!
Glencore : Glencore announces the final price of convertible bonds » Report
Roche: CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis » Report
Julius Bär Warrants - New Issues » Report
Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia » Report